Clinical trials: Aspergillus Infection
Invasive Fungal Infections
Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options
A study to evaluate olorofim (F901318) for the treatment of invasive fungal infections in participants lacking suitable alternative treatment options.
- Trial name
- FORMULA-OLS (NCT03583164)
- Testing
- Olorofim
- Where
- 82 sites in United States, Australia and 15 more
- Volunteers
- 203 people
- Sponsor
- F2G Biotech GmbH
Invasive Aspergillosis, Mucormycosis
A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.
This is a non-interventional medical chart review study aiming to examine the effectiveness, safety, and treatment patterns of isavuconazole in 5 European countries (France, Germany, Italy, Spain, and United Kingdom).
- Trial name
- PRISMA (NCT04550936)
- Testing
- Isavuconazole
- Where
- 15 sites in France, Germany and 3 more
- Volunteers
- 307 people
- Sponsor
- Pfizer
Fungal Infection
A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)
The purpose of this study is to investigate the safety and efficacy of MK0991 in patients with deep-seated mycoses.
- Trial name
- NCT00717860
- Testing
- caspofungin acetate, Comparator: Micafungin sodium
- Volunteers
- 121 people
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Aspergillosis
Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)
This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to <18 years of age with invasive aspergillosis (IA).
- Trial name
- NCT04218851
- Testing
- Posaconazole IV, Posaconazole PFS, Posaconazole tablet
- Where
- 29 sites in United States, Belgium and 8 more
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Candidiasis, Mucocutaneous Candidiasis
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or…
- Conditions
- Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis
- Trial name
- FURI (NCT03059992)
- Testing
- Ibrexafungerp
- Where
- 37 sites in United States, Austria and 6 more
- Volunteers
- 233 people
- Sponsor
- Scynexis, Inc.
Fungal Infections, Invasive Pulmonary Aspergillosis
A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)
The purpose of this study is to evaluate the safety and efficacy of posaconazole (POS) versus voriconazole (VOR) in the treatment of adults and adolescents with invasive aspergillosis (IA).
- Trial name
- NCT01782131
- Testing
- Posaconazole, Voriconazole
- Volunteers
- 585 people
- Sponsor
- Merck Sharp & Dohme LLC
Systemic Mycosis
Voriconazole (Vfend) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
To collect the efficacy and safety informations of voriconazole related to their appropriate use in daily practice.
- Trial name
- NCT01151085
- Testing
- Voriconazole
- Volunteers
- 1,002 people
- Sponsor
- Pfizer
Aspergillosis, Aspergilloma
Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection
In this study we will measure the concentration of the drug called voriconazole which is used to fight infections caused by fungus in children who usually are cancer patients and have their immune system down.
- Trial name
- NCT01383993
- Testing
- Voriconazole
- Where
- 6 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Pfizer
Aspergillosis
Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis
This study compares the effectiveness and safety of the combination of anidulafungin and voriconazole compared to that of voriconazole alone (which is generally considered the standard of care) for the treatment of Invasive…
- Trial name
- NCT00531479
- Testing
- voriconazole, anidulafungin
- Where
- 107 sites in United States, Australia and 22 more
- Volunteers
- 459 people
- Sponsor
- Pfizer
Invasive Aspergillosis
Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis
This study investigates the safety and tolerability as well as the efficacy and pharmacokinetics of caspofungin in four escalating dosages in adult patients with hematologic malignancies and proven or probable invasive…
- Trial name
- NCT00404092
- Testing
- caspofungin
- Where
- 4 sites in Belgium, Germany
- Volunteers
- 46 people
- Sponsor
- University of Cologne
Cystic Fibrosis
Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients
This study is designed to assess the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics (proof of concept) of QBW251 in healthy subjects and cystic fibrosis patients following single and multiple doses.
- Trial name
- NCT02190604
- Testing
- QBW251
- Where
- 23 sites in United States, Belgium and 5 more
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Allergic Bronchopulmonary Aspergillosis
Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
The primary safety objectives were: Part 1: To determine the safety and tolerability of single doses of ZP-059 in healthy subjects Part 2: To determine the safety and tolerability of multiple doses of ZP-059 in subjects with mild…
- Trial name
- NCT04229303
- Testing
- Voriconazole inhaled, oral voriconazole
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Zambon SpA
Mycoses, Candidiasis
A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection
The purpose of this study is to assess the pharmacokinetics (how the drug is absorbed in the body, distributed within the body, and how it is removed from the body over time) of itraconazole (ITCZ) oral solution in participants…
- Conditions
- Mycoses, Candidiasis, Aspergillosis, Cryptococcosis
- Trial name
- NCT00784368
- Testing
- ITCZ Oral Solution, ITCZ-IV
- Where
- Japan
- Volunteers
- 55 people
- Sponsor
- Janssen Pharmaceutical K.K.
COVID-19 Respiratory Infection, Aspergillosis
Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
COVID-19 associated pulmonary aspergillosis (CAPA) is considered a potentially life-threatening infection in critically ill COVID (Corona Virus disease)-19 patients.
- Trial name
- POSACOVID (NCT05065658)
- Testing
- Posaconazole
- Where
- 3 sites in Austria, France and 1 more
- Volunteers
- 249 people
- Sponsor
- Medical University of Graz
Pulmonary Aspergillosis
An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)
A study to evaluate the safety and tolerability of opelconazole for the prevention of fungal aspergillus infections in the lung in participants who have received a lung transplant.
- Trial name
- NCT05037851
- Testing
- Opelconazole, Standard of Care
- Where
- 19 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Pulmocide Ltd
Aspergillosis
Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)
The primary objective of this study is to assess and compare the safety of posaconazole with voriconazole in Japanese participants with aspergillosis.
- Trial name
- NCT02180165
- Testing
- Posaconazole, Voriconazole
- Volunteers
- 116 people
- Sponsor
- Merck Sharp & Dohme LLC
Candidiasis, Esophageal, Candidiasis, Invasive
A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)
The study estimates the safety, efficacy, and pharmacokinetics of caspofungin (MK-0991) in Japanese children and adolescents with documented Candida or Aspergillus infections.
- Conditions
- Candidiasis, Esophageal, Candidiasis, Invasive, Aspergillosis
- Trial name
- NCT01165320
- Testing
- Caspofungin
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Pulmonary Aspergillosis, Lymphoblastic Leukaemia
Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia
The trial evaluates the overall tolerability of the drug and the efficacy of aerosolised amphotericin B as a lipid complex (ABLC) for primary prophylaxis of invasive pulmonary aspergillosis (IPA) in pediatric patients with acute…
- Conditions
- Invasive Pulmonary Aspergillosis, Lymphoblastic Leukaemia, Myeloblastic Leukaemia, Lymphoblastic Leukemia
- Trial name
- NCT01615809
- Testing
- AMPHOTERICIN B
- Where
- Spain
- Volunteers
- 32 people
- Sponsor
- Fundació Sant Joan de Déu
Invasive Fungal Infections
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).
- Trial name
- AEGIS (NCT04240886)
- Testing
- fosmanogepix
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 21 people
- Sponsor
- Basilea Pharmaceutica
Invasive Aspergillosis
F901318 Single Ascending Dose Study in Healthy Male Volunteers
F901318 is a potent new antifungal agent for the treatment of systemic fungal infections. This study will test it for the first time in man with the objective of assessing its safety, tolerability and pharmacokinetic profile.
- Trial name
- NCT02142153
- Testing
- F901318
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- F2G Ltd